EP4240849A4 - OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM - Google Patents

OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM

Info

Publication number
EP4240849A4
EP4240849A4 EP21890258.3A EP21890258A EP4240849A4 EP 4240849 A4 EP4240849 A4 EP 4240849A4 EP 21890258 A EP21890258 A EP 21890258A EP 4240849 A4 EP4240849 A4 EP 4240849A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotide compositions
oligonucleotide
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21890258.3A
Other languages
German (de)
French (fr)
Other versions
EP4240849A1 (en
Inventor
Prashant Monian
Chikdu Shakti Shivalila
Subramanian Marappan
Chandra Vargeese
Pachamuthu Kandasamy
Genliang Lu
Hui Yu
David Charles Donnell Butler
Luciano Henrique Apponi
Mamoru Shimizu
Stephany Michelle Standley
David John Boulay
Andrew Guzior Hoss
Jigar Desai
Jack David Godfrey
Hailin Yang
Naoki Iwamoto
Jayakanthan Kumarasamy
Anthony Lamattina
Tom Liantang Pu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wave Life Sciences Pte Ltd
Original Assignee
Wave Life Sciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Pte Ltd filed Critical Wave Life Sciences Pte Ltd
Publication of EP4240849A1 publication Critical patent/EP4240849A1/en
Publication of EP4240849A4 publication Critical patent/EP4240849A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21890258.3A 2020-11-08 2021-11-08 OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM Pending EP4240849A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063111079P 2020-11-08 2020-11-08
US202163175036P 2021-04-14 2021-04-14
US202163188415P 2021-05-13 2021-05-13
US202163196178P 2021-06-02 2021-06-02
US202163248520P 2021-09-26 2021-09-26
PCT/US2021/058495 WO2022099159A1 (en) 2020-11-08 2021-11-08 Oligonucleotide compositions and methods thereof

Publications (2)

Publication Number Publication Date
EP4240849A1 EP4240849A1 (en) 2023-09-13
EP4240849A4 true EP4240849A4 (en) 2026-04-01

Family

ID=81456778

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21890258.3A Pending EP4240849A4 (en) 2020-11-08 2021-11-08 OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM

Country Status (8)

Country Link
EP (1) EP4240849A4 (en)
JP (1) JP2023548584A (en)
KR (1) KR20230118716A (en)
AU (1) AU2021373062A1 (en)
CA (1) CA3197311A1 (en)
IL (1) IL302558A (en)
MX (1) MX2023005326A (en)
WO (1) WO2022099159A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (en) 2015-07-22 2024-05-03 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof
MA46427A (en) 2015-10-09 2018-08-15 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (en) 2017-09-18 2020-05-05 波涛生命科学有限公司 Oligonucleotide Preparation Technology
JP2021521140A (en) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. Oligonucleotide composition and its usage
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (en) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Oligonucleotide compositions and methods of use thereof.
CN115989041A (en) * 2020-08-24 2023-04-18 波涛生命科学有限公司 Cells and non-human animals engineered to express ADAR1 and uses thereof
WO2023278410A1 (en) * 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
EP4404942A4 (en) * 2021-09-26 2026-06-17 Wave Life Sciences Ltd COMPOSTURES FOR PROCESSING MECP2 TRANSCRIPTS AND METHODS FOR DOING SO
CA3232070A1 (en) * 2021-09-26 2023-03-30 Prashant MONIAN Oligonucleotide compositions and methods thereof
AU2022370009A1 (en) * 2021-10-22 2024-05-16 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4558632A1 (en) * 2022-07-18 2025-05-28 F. Hoffmann-La Roche AG Editing oligonucleotide
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (en) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. Antisense oligonucleotides for the treatment of hereditary hemochromatosis-HFE
US20250101418A1 (en) 2022-11-30 2025-03-27 Eberhard-Karls-Universität-Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
JP2026510408A (en) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024220934A1 (en) 2023-04-21 2024-10-24 University Of Rochester Nucleic acid molecules for pseudouridylation
CN116444593B (en) * 2023-04-28 2023-12-26 南通大学 Synthesis method of 7-deazaguanosine phosphoramidite monomer
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4743577A1 (en) * 2023-07-13 2026-05-20 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof
EP4762176A1 (en) 2023-08-15 2026-06-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
CN122555564A (en) * 2023-09-28 2026-08-11 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof
EP4784593A2 (en) * 2023-09-28 2026-08-05 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025073902A1 (en) 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025083268A1 (en) 2023-10-20 2025-04-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) * 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
AU2025211865A1 (en) * 2024-01-22 2026-08-13 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
WO2025172372A1 (en) 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
GB202405143D0 (en) 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026080897A1 (en) 2024-10-11 2026-04-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of chronic pain
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
WO2026136804A1 (en) 2024-12-20 2026-06-25 Denali Therapeutics Inc. Compositions and methods for modulating synuclein expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004189A1 (en) * 1998-07-14 2000-01-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides
WO2001023613A1 (en) * 1999-09-30 2001-04-05 Isis Pharmaceuticals, Inc. Human rnase h and oligonucleotide compositions thereof
WO2018057946A2 (en) * 2016-09-23 2018-03-29 Board Of Trustees Of Southern Illinois University Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
WO2020001793A1 (en) * 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
WO2020154344A1 (en) * 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074597A1 (en) * 2012-11-06 2014-05-15 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
WO2018041973A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
KR102678809B1 (en) * 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 Systems, methods and compositions for targeted nucleic acid editing
WO2018237194A1 (en) * 2017-06-21 2018-12-27 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004189A1 (en) * 1998-07-14 2000-01-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides
WO2001023613A1 (en) * 1999-09-30 2001-04-05 Isis Pharmaceuticals, Inc. Human rnase h and oligonucleotide compositions thereof
WO2018057946A2 (en) * 2016-09-23 2018-03-29 Board Of Trustees Of Southern Illinois University Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
WO2020001793A1 (en) * 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
WO2020154344A1 (en) * 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANZAHAEE MARYAM YAHYAEE ET AL: "Arabinonucleic Acids: 2'-Stereoisomeric Modulators of siRNA Activity", NUCLEIC ACID THERAPEUTICS, vol. 24, no. 5, 11 September 2014 (2014-09-11), US, pages 336 - 343, XP093060210, ISSN: 2159-3337, Retrieved from the Internet <URL:https://www.liebertpub.com/doi/pdf/10.1089/nat.2014.0496> DOI: 10.1089/nat.2014.0496 *
DELEAVEY G. F. ET AL: "Designing chemically modified common general oligonucleotides for targeted gene silencing", CHEM BIOL., vol. 19, no. 8, 23 August 2012 (2012-08-23), pages 937 - 954, XP055905926 *
HABIBIAN MARYAM ET AL: "Effect of 2'-5'/3'-5' phosphodiester linkage heterogeneity on RNA interference", NUCLEIC ACIDS RESEARCH, vol. 48, no. 9, 21 May 2020 (2020-05-21), GB, pages 4643 - 4657, XP093134741, ISSN: 0305-1048, Retrieved from the Internet <URL:https://watermark.silverchair.com/gkaa222.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2UwggNhBgkqhkiG9w0BBwagggNSMIIDTgIBADCCA0cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMPjlmya_Sg5wroXc0AgEQgIIDGAtyt6-G8374AZjr4A3wDFG15Dqe98ZmkUBqGbtljI3egSWUPRJ0P-qPfIP__lSS7nCSd7WbHoJsFLT4MkQUV6x95y_O> DOI: 10.1093/nar/gkaa222 *
PRAKASH ET AL: "RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 12, 15 June 2006 (2006-06-15), pages 3238 - 3240, XP005422615, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2006.03.053 *
PRAKASH T P ET AL: "RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 12, 15 June 2006 (2006-06-15), pages 3238 - 3240, XP027965587, ISSN: 0960-894X, [retrieved on 20060615] *
See also references of WO2022099159A1 *
SHEN WEN ET AL: "2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF", NUCLEIC ACIDS RESEARCH, vol. 43, no. 9, 19 May 2015 (2015-05-19), GB, pages 4569 - 4578, XP055863433, ISSN: 0305-1048, Retrieved from the Internet <URL:https://academic.oup.com/nar/article-pdf/43/9/4569/5153015/gkv298.pdf> DOI: 10.1093/nar/gkv298 *

Also Published As

Publication number Publication date
MX2023005326A (en) 2023-07-31
EP4240849A1 (en) 2023-09-13
AU2021373062A1 (en) 2023-06-08
IL302558A (en) 2023-07-01
CA3197311A1 (en) 2022-05-12
JP2023548584A (en) 2023-11-17
AU2021373062A9 (en) 2024-10-24
KR20230118716A (en) 2023-08-11
WO2022099159A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
EP4396354A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM
EP4153604A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREFOR
EP3694530A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
EP3664815A4 (en) OLIGONUCLEOTIDIC COMPOSITIONS AND ASSOCIATED METHODS
EP4422645A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEM USE
EP4114360A4 (en) COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY
EP4153771A4 (en) COMPOSITIONS AND METHODS FOR DNA CYTOSINE CARBOXYMETHYLATION
EP3891284A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
EP4217477A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION
EP4399306A4 (en) PAH-MODULING COMPOSITIONS AND METHODS
EP4185569C0 (en) METHODS AND COMPOSITIONS FOR TARGETING PD-L1
EP4153567A4 (en) METHODS AND COMPOSITIONS FOR TARGETING PD-L1
EP4337202A4 (en) Methods and compositions for targeting PD-L1
EP4399309A4 (en) SERPINAMODULATING COMPOSITIONS AND PROCEDURES
EP3500676A4 (en) METHOD AND COMPOSITIONS FOR TARGETED GENE TRANSFER
EP4419677A4 (en) DNA COMPOSITIONS AND RELATED METHODS
EP4408995A4 (en) COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS
EP4410067A4 (en) Tool and method for placement arrangement
EP4380576A4 (en) COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERIES
EP4304774A4 (en) CEMENT COMPOSITIONS AND METHODS THEREFOR
EP4486901A4 (en) COMPOSITIONS AND METHODS FOR GENOMEDITATION
EP4448512A4 (en) METHODS AND COMPOSITIONS FOR TARGETING PD-L1
EP4463173A4 (en) Postbiotic compositions and methods
EP4146151A4 (en) FURAN-SURFACTANT COMPOSITIONS AND METHODS
EP3757909C0 (en) METHOD AND SYSTEM FOR DESIGNING FORMULATED PRODUCTS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100318

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20251205BHEP

Ipc: C12N 9/22 20060101ALI20251205BHEP

Ipc: A61K 31/712 20060101ALI20251205BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20260304

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20260226BHEP

Ipc: C12N 9/22 20060101ALI20260226BHEP

Ipc: A61K 31/712 20060101ALI20260226BHEP